European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candidaemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/country determined by population size) included ∼10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin resistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25-33%) while Italy and Turkey had the highest C. parapsilosis proportions (24-26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Self-citationAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509
Nosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502
ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12038 · Cited by 386
Self-citationLortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Global epidemiology of emerging Candida auris
Rhodes, J., & Fisher, M. C. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.05.008 · Cited by 315
Research works printed but not linked: 32
- Nielsen, 1991, Fungemia in a university hospital 1984–1988, Scand J Infect Dis, 23, 275, 10.3109/00365549109024310 · DOI · Paper page
- Bretagne, 2022, Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF Network (2012 to 2018), mBio, 13, 10.1128/mbio.00920-22 · DOI
- Risum, 2021, Update 2016–2018 of the nationwide danish fungaemia surveillance study: epidemiologic changes in a 15-year perspective, J Fungi, 7, 491, 10.3390/jof7060491 · DOI
- Mamali, 2022, Increasing incidence and shifting epidemiology of candidemia in Greece: results from the first nationwide 10-year survey, J Fungi, 8, 1, 10.3390/jof8020116 · DOI
- Díaz-García, 2022, Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris, J Antimicrob Chemother, 77, 3102, 10.1093/jac/dkac288 · DOI · Paper page
- Plachouras, 2020, Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area, january 2018 to may 2019, Eurosurveillance, 25, 1, 10.2807/1560-7917.ES.2020.25.12.2000240 · DOI
- Rogers, 2022, Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications, J Antimicrob Chemother, 77, 2053, 10.1093/jac/dkac161 · DOI · Paper page
- Díaz-García, 2021, Antifungal susceptibility testing identifies the abdominal cavity as a source of candida glabrata-resistant isolates, Antimicrob Agents Chemother, 65, 10.1128/AAC.01249-21 · DOI
- Jensen, 2016, Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study, Antimicrob Agents Chemother, 60, 1500, 10.1128/AAC.01763-15 · DOI · Paper page
- Goemaere, 2018, Clonal spread in Candida glabrata bloodstream isolates and fluconazole resistance affected by prolonged exposure: a 12-year single-center study in Belgium, Antimicrob Agents Chemother, 62, 10.1128/AAC.00591-18 · DOI
- Sarvikivi, 2005, Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit, J Clin Microbiol, 43, 2729, 10.1128/JCM.43.6.2729-2735.2005 · DOI · Paper page
- Alcoceba, 2022, Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain, Clin Microbiol Infect, 28, 1113, 10.1016/j.cmi.2022.02.025 · DOI · Paper page
- Trevijano-Contador, 2022, Global emergence of resistance to fluconazole and voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic, Open Forum Infect Dis, 1
- Ramos-Martínez, 2022, Impact of the COVID-19 pandemic on the clinical profile of candidemia and the incidence of fungemia due to fluconazole-resistant Candida parapsilosis, J Fungi, 8, 451, 10.3390/jof8050451 · DOI
- Daneshnia, 2022, Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU, Emerg Microbes Infect, 11, 2264, 10.1080/22221751.2022.2117093 · DOI
- Koehler, 2019, ECMM CandiReg—a ready to use platform for outbreaks and epidemiological studies, Mycoses, 62, 920, 10.1111/myc.12963 · DOI
- Hoenigl, 2023, Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study, Lancet Infect Dis, 23, 751, 10.1016/S1473-3099(22)00872-6 · DOI · Paper page
- Salmanton-García, 2021, EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19, HemaSphere, 5, 10.1097/HS9.0000000000000612 · DOI
- Hoenigl, 2018, Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together, Mycoses, 61, 885, 10.1111/myc.12836 · DOI · Paper page
- Normand, 2017, Validation of a new web application for identification of fungi by use of matrix-assisted laser desorption ionization–time of flight mass spectrometry, J Clin Microbiol, 55, 2661, 10.1128/JCM.00263-17 · DOI
- Arendrup, 2016, EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents, Clin Microbiol Infect, 22, 10.1016/j.cmi.2016.01.017 · DOI
- Arendrup, 2021, ISO standard 20776-1 or serial 2-fold dilution for antifungal susceptibility plate preparation: that is the question!, J Antimicrob Chemother, 76, 1793, 10.1093/jac/dkab088 · DOI
- Arendrup, 2020, How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clin Microbiol Infect, 26, 1464, 10.1016/j.cmi.2020.06.007 · DOI · Paper page
- Astvad, 2022, A pragmatic approach to susceptibility classification of yeasts without EUCAST clinical breakpoints, J Fungi, 8, 141, 10.3390/jof8020141 · DOI
- Astvad KMTT, 2018, Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern, J Clin Microbiol, 56, 1
- Arastehfar, 2021, Clonal candidemia outbreak by Candida parapsilosis carrying Y132F in Turkey: evolution of a persisting challenge, Front Cell Infect Microbiol, 11, 1, 10.3389/fcimb.2021.676177 · DOI · Paper page
- Martini, 2020, Prevalence and clonal distribution of azole-resistant Candida parapsilosis isolates causing bloodstream infections in a large Italian hospital, Front Cell Infect Microbiol, 10, e232, 10.3389/fcimb.2020.00232 · DOI · Paper page
- Singh, 2019, Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India, J Antimicrob Chemother, 74, 1260, 10.1093/jac/dkz029 · DOI
- Chiotos, 2016, Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12): Table 1, J Antimicrob Chemother, 71, 3536, 10.1093/jac/dkw305 · DOI · Paper page
- Siopi, 2022, Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 alteration in a patient with prolonged echinocandin therapy, J Fungi, 8, 931, 10.3390/jof8090931 · DOI
- Moudgal, 2005, Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis, Antimicrob Agents Chemother, 49, 767, 10.1128/AAC.49.2.767-769.2005 · DOI · Paper page
- Arastehfar, 2021, Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?, J Antimicrob Chemother, 76, 418, 10.1093/jac/dkaa419 · DOI · Paper page
Cited by
Salmanton-García, J., Cornely, O. A., Stemler, J., Barać, A., Steinmann, J., Siváková, A., Akalin, E. H., Arikan-Akdagli, S., Loughlin, L., Toscano, C., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106229 · Cited by 127
Self-citationApproaches for identifying and measuring heteroresistance in azole-susceptible Candida isolates
Gautier, C., Maciel, E. I., & Ene, I. V. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04041-23 · Cited by 23
Meng, Q., Wang, H., Xiao, W., Mai, W., Liu, Y., Xiao, Y., Wang, P., Sui, J., He, X., Yin, F., et al. (2025) · Mycology · doi:10.1080/21501203.2025.2461725 · Cited by 8
Liao, B., Zhang, C., Shen, J., Chen, D., Wang, J., Chen, X., Zhou, Y., Wei, Y., Shi, Y., Gou, L., et al. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13411-7 · Cited by 7
Metadata
- Authors
- Arendrup, M. C., Arikan-Akdagli, S., Jørgensen, K. M., Barac, A., Steinmann, J., Toscano, C., Arsenijevic, V. A., Sartor, A., Lass-Flörl, C., Hamprecht, A., Matos, T., Rogers, B. R. S., Quiles, I., Buil, J., Özenci, V., Krause, R., Bassetti, M., Loughlin, L., Denis, B., Grancini, A., White, P. L., Lagrou, K., Willinger, B., Rautemaa-Richardson, R., Hamal, P., Ener, B., Unalan-Altintop, T., Evren, E., Hilmioglu-Polat, S., Oz, Y., Ozyurt, O. K., Aydin, F., Růžička, F., Meijer, E. F. J., Gangneux, J. P., Lockhart, D. E. A., Khanna, N., Logan, C., Scharmann, U., Desoubeaux, G., Roilides, E., Talento, A. F., van Dijk, K., Koehler, P., Salmanton-García, J., Cornely, O. A., & Hoenigl, M.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 87
- Issue
- 5
- Pages
- 428-437
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W4385613059
- Cited by
- 123
- References
- 25
- FWCI
- 23.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Hacettepe Üniversitesi
- Statens Serum Institut
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study. https://app.cochat.ai/papers/10.1016/j.jinf.2023.08.001
- The paper
- Arendrup, M. C., Arikan-Akdagli, S., Jørgensen, K. M., Barac, A., Steinmann, J., Toscano, C., Arsenijevic, V. A., Sartor, A., Lass-Flörl, C., Hamprecht, A., Matos, T., Rogers, B. R. S., Quiles, I., Buil, J., Özenci, V., Krause, R., Bassetti, M., Loughlin, L., Denis, B., . . . Hoenigl, M. (2023). European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study. Journal of Infection. https://doi.org/10.1016/j.jinf.2023.08.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.